Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Additive effect of Apo2L/TRAIL and Adeno-p53 in the induction of apoptosisin myeloma cell lines
Autore:
Liu, Q; El-Deiry, WS; Gazitt, Y;
Indirizzi:
Univ Texas, Hlth Sci Ctr, Dept Med Hematol, San Antonio, TX 78229 USA UnivTexas San Antonio TX USA 78229 ed Hematol, San Antonio, TX 78229 USA Penn Sch Med, Howard Hughes Med Inst, Lab Cell Cycle Regulat, Philadelphia, PA USA Penn Sch Med Philadelphia PA USA ell Cycle Regulat, Philadelphia, PA USA
Titolo Testata:
EXPERIMENTAL HEMATOLOGY
fascicolo: 8, volume: 29, anno: 2001,
pagine: 962 - 970
SICI:
0301-472X(200108)29:8<962:AEOAAA>2.0.ZU;2-R
Fonte:
ISI
Lingua:
ENG
Soggetto:
P53 GENE-TRANSFER; DEXAMETHASONE-INDUCED APOPTOSIS; BONE-MARROW TRANSPLANTATION; TRAIL-INDUCED APOPTOSIS; HUMAN MULTIPLE-MYELOMA; LUNG-CANCER; IN-VIVO; BCL-2 OVEREXPRESSION; ANTITUMOR-ACTIVITY; TUMOR SUPPRESSION;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
55
Recensione:
Indirizzi per estratti:
Indirizzo: Gazitt, Y Univ Texas, Hlth Sci Ctr, Dept Med Hematol, Mail Code 7880,7703 Floyd CurlDr, San Antonio, TX 78229 USA Univ Texas Mail Code 7880,7703 Floyd Curl Dr San Antonio TX USA 78229
Citazione:
Q. Liu et al., "Additive effect of Apo2L/TRAIL and Adeno-p53 in the induction of apoptosisin myeloma cell lines", EXP HEMATOL, 29(8), 2001, pp. 962-970

Abstract

Objectives. We have previously shown that Adenovirus-p53 (Ad-p53) is a potent inducer of apoptosis in myeloma cells expressing nonfunctional p53 and low levels of bcl-2 and that Apo2L/TRAIL is a potent inducer of apoptosis, independent of bcl-2. A study was designed to test the synergy between Ad-p53 and Apo2L/TRAIL in the induction of apoptosis in relation to the expression of DR4/DR5 and DcR1, in cells undergoing Ad-p53-induced apoptosis. Methods. Replication deficient Ad-p53 and human recombinant Apo2L/TRAIL were used. Myeloma cells with mutated/w.t. p53 and varying expression of bcl-2 were used to test the effect of Ad-p53, Apo2L/TRAIL, or both, on apoptosis, measured by annexin V. Results. Treatment with Ad-p53 resulted in a dose-dependent apoptosis concomitant with a dose-dependent increase in the expression of DR4/DR5 and a decrease in the expression of DcR1, in Ad-p53-sensitive cell lines. In thesecells, addition of Apo2L/TRAIL to cells treated with Ad-p53 resulted in a dose-dependent increase in apoptosis. Myeloma cells resistant to Ad-p53 hadhigh levels of DR4/DR5 and high levels of DcR1 and treatment with Ad-p53 did not reduce the expression of DcR1. Also, addition of Apo2L/TRAIL to Ad-p53 did not affect the level of apoptosis beyond the level of apoptosis observed with Apo2L/TRAIL alone. Conclusions. 1) Cotreatment with Ad-p53 and Apo2L/TRAIL resulted in additive apoptosis in myeloma cells expressing nonfunctional p53 and low levels of bcl-2. 2) Resistance to Ad-p53 or to the combination of Ad-p53 and Apo2L/TRAIL was not due to the lack of adenovirus receptor (CAR) or low expression of DR4/DR5 but rather due to the relatively high expression of DcR1 receptor. (C) 2001 International Society for Experimental Hematology. Published by Elsevier Science Inc.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/11/20 alle ore 01:18:15